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Abstract
A new spectrophotometric method is developed for the determination of phenylpropanolamine HCl (PPA),
ephedrine HCl (EPH) and pseudoephedrine HCl (PSE) in pharmaceutical preparations and spiked human urine. The
method involved heat-catalyzed derivatization of the three drugs with 2,4-dinitrofluorobenzene (DNFB) producing a
yellow colored product peaking at 370 nm for PPA and 380 nm for EPH and PSE, respectively.
The absorbance concentration plots were rectilinear over the range of 2-20 for PPA and 1-14 μg/mL for both of
EPH and PSE, respectively. The limit of detection (LOD) values were 0.20, 0.13 and 0.20 μg/mL for PPA, EPH and
PSE, respectively and limit of quantitation (LOQ) values of 0.60 and 0.40 and 0.59 μg/mL for PPA, EPH and PSE,
respectively. The analytical performance of the method was fully validated and the results were satisfactory. The
proposed method was successfully applied to the determination of the three studied drugs in their commercial
dosage forms including tablets, capsules and ampoules with good percentage recoveries. The proposed method
was further applied for the determination of PSE in spiked human urine with a mean percentage recovery of
108.17 ± 1.60 for (n = 3). Statistical comparison of the results obtained with those of the comparison methods
showed good agreement and proved that there was no significant difference in the accuracy and precision
between the two methods. The mechanism of the reaction pathway was postulated.
1. Introduction
Phenylpropanolamine hydrochloride, (PPA) is (1RS, 2SR)-
2-amino-1-phenylpropanol hydrochloride [1] (Figure 1). It
is a largely indirect acting sympathomimetic with an
action similar to ephedrine; it is orally administered for
the treatment of nasal congestion. It is frequently used in
mixture preparations for the relief of cough and cold
symptoms. Other uses of phenylpropanolamine include;
the control of the urinary incontinence in some patients.
It has also been used to suppress appetite in the manage-
ment of obesity [1]. The United States Pharmacopoeia
(USP) [2] and the British Pharmacopoeia (BP) [3] recom-
mended non-aqueous titrimetric method for the determi-
nation of PPA in the pure form in presence of mercuric
acetate, using perchloric acid as a titrant and crystal violet
as indicator. On the other hand, USP [2] recommended
HPLC method for its determination in dosage forms using
a mixture of (1-hexanesulfonate, monobasic sodium phos-
phate and triethylammonium phosphate) and methanol as
a mobile phase with UV detection at 210 nm.
Due to its clinical advantages, PPA received a great
interest. A good guide to the work published is found as
comprehensive monograph in analytical profiles for
drugs [4]. Several analytical techniques have been
reported for PPA determination either perse or in phar-
maceutical preparations and biological fluids including;
titrimetry [5], spectrophotometry [6], fluorimetry [7],
HPLC [8], capillary electrophoresis [9], flow injection
[10] and gas chromatography [11].
Ephedrine hydrochloride (EPH) is (1R, 2S)-2-(Methyla-
mino)-1-phenylpropan-1-ol hydrochloride [1] (Figure 1). It
is a sympathomimetic drug with direct and indirect effects
on adrenergic receptors. It has alpha and beta-adrenergic
activity and has pronounced stimulating effects on the cen-
tral nervous system [1]. It is reported to reduce the viscos-
ity of tenacious sputum and is used as an expectorant. The
USP [2] recommended a non aqueous titration method for
its determination in pure form in presence of mercuric
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acetate and titration with 0.1N perchloric acid using crystal
violet as indicator. The BP [12] favored a potentiometric
titration method for its determination in pure form using
0.1 M NaOH as a titrant. Both of USP and BP recom-
mended HPLC method with UV detection at 263 nm for
its determination in dosage forms. Various reports have
been described for the analysis of EPH A good guide to the
work published for EPH is found as comprehensive mono-
graph in analytical profiles for drug substances [13]. Several
techniques were reported for its determination including;
titrimetry [14], spectrophotometry [15], fluorimetry [16],
flow injection [17], capillary electrophoresis [18], TLC [19],
HPLC [20], and gas chromatography [21].
Pseudoephedrine HCl (PSE) is (1S, 2S)-2-(Methyla-
mino)-1-phenylpropan-1-ol hydrochloride [1] (Figure 1)
is a direct and indirect sympathomimetic. It is a stereoi-
somer of ephedrine and has a similar action, but has
been stated to have less pressor activity and fewer CNS
effects. It is given orally for the relief of nasal congestion.
They are commonly combined with other ingredients for
the relief of cough and cold symptoms [1]. Also the USP
[2] recommended a non aqueous titration method for the
determination of PSE in its pure form in presence of
mercuric acetate and titration with 0.1 M perchloric acid
using crystal violet as indicator. The BP [12] preferred a
potentiometric titration for its determination in pure
form using 0.1 M NaOH as a titrant. Both USP and BP
recommended HPLC method with UV detection at 254
nm and 258 nm, respectively, for its determination in
dosage forms.
A good guide to the work published for PSE is found as
comprehensive monograph in analytical profiles for drugs
[22]. The literature revealed that the analysis of PSE was
through techniques such as; spectrophotometry [23], flow
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Figure 1 Structural formulae of the three studied drugs.
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Sanger’s reagent (DNFB), on the other hand, has been
utilized as a chromogen for the spectrophotometric esti-
mation of many compounds of pharmaceutical interest




- A shimadzu UV-Visible 1601 PC spectrophotometer
(Kyoto, Japan) was used for spectrophotometric measure-
ments (P/N 206-67001). The recording range was 0-1.2
- A consort NV P901 digital pH Meter (Belgium) cali-
brated with standard buffers was used for checking the pH
of the buffer solutions used.
- Sigma laborzentrifugen (2-16p) Centrifuge (Germany).
2.2. Materials and Solutions
All the reagents used were of Analytical Grade and dis-
tilled water was used throughout the work.
-Phenylpropanolamine HCl, batch # 41204 and ephe-
drine HCl, batch #135705, were kindly supplied from
Egyptian Pharmaceutical Industries CO. E.P.I.CO (10th of
Ramadan-Egypt) with purity of 100.55% and 100.99% for
PPA and EPH, respectively as determined by the official
method [12].
-Pseudoephedrine HCl, batch # 050727 was kindly pro-
vided from Sigma Company, its purity was 99.65% which
was determined according to official method [12].
-2, 4 dinitrofluorobenzene (DNFB) (Fluka Chemie,
Germany) was freshly prepared as 0.3% (v/v) methanolic
solution.
-Borate buffer solution (0.2 M) was prepared by mixing
appropriate volumes of 0.2 M boric acid and 0.2 M
NaOH and adjusting the pH using a pH Meter. The buf-
fer solution was kept in the refrigerator and left to reach
the room temperature before use.
-Methanol, hydrochloric acid (32%), boric acid and
tween-80 were purchased from (BDH, UK).
-Cetyltrimethylammonium bromide (cetrimide) was
obtained from Merck (Darmstadt, Germany), 1%, (w/v)
aqueous solution was prepared.
-Sodium dodecyl sulphate (SDS) 95% was obtained
from Winlab (Middlesex, England), 1%, (w/v) aqueous
solution was used.
-Urine samples were obtained from a healthy female
volunteer around 30 years.
The following dosage forms containing the drugs were
purchased from local Pharmacies:
-Allercet capsules, batch # 820304, each capsule
labeled to contain 30 mg PSE and 10 mg cetirizine HCl,
product of Global Napi Pharmaceuticals, 6th of October
City-Giza-Egypt.
-Contaflu tablets, batch # 061342, each tablet labeled to
contain 24 mg of PPA, 3 mg of chlorpheniramine maleate
and 200 mg of propyphenazone, product of Egyptian Int.
Pharmaceutical Industries CO. E.P.I.CO,10th of Ramadan
City, Egypt.
-Ephedrine ampoule, batch # 11, each ampoule (1 mL)
labeled to contain 30 mg of EPH, product of Chemical
industries Development(CID)-Giza-A.R.E.
2.3. Standard solutions
Standard stock solutions of the studied drugs were pre-
pared by dissolving 10.0 mg of each of the studied drugs
in 100 mL of distilled water. Serial dilution with the same
solvent was performed to obtain the appropriate concen-
tration range. These solutions were stable for at least
10 days when kept in the refrigerator and protected from
light.
2.4. General Analytical Procedures
2.4.1. Construction of the Calibration Curves
Aliquot volumes of PPA, EPH and PSE standard solutions
covering the working concentration ranges were trans-
ferred in to a series of screw capped test tubes, followed
by specific volume of borate buffer at pH 8.0. Then, the
specific volume of 3% (v/v) of DNFB was added. The test
tubes were heated in a thermostatically controlled water
bath at 70°C in case of PSE and at 80°C in case of EPH
and PPA, respectively. The solutions were heated for 25
min in case of PSE, EPH and for 20 min in case of PPA,
respectively. The reaction was stopped by cooling under
tap water, then 0.2 mL of concentrated HCl was added
and the contents of the test tubes were then transferred in
to 10 mL volumetric flasks, diluted to the volume with
specific solvent and mixed well. The absorbance of the
resulted product was measured at 370 nm in case of PPA
and at 380 nm for EPH and PSE, respectively against a
reagent blank prepared simultaneously. The absorbance of
the resulted solution was plotted versus the final concen-
tration of the drug (μg/mL) to obtain the calibration
graphs. Alternatively, the corresponding regression equa-
tions were derived.
2.4.2. Application of the Proposed Method to the Analysis
of the Studied Drugs in their Dosage Forms
• For tablets and capsules:
An accurately weighed quantity of the mixed contents of
ten capsules or powdered tablets equivalent to 10.0 mg of
PSE or PPA were transferred into conical flask and
extracted with 3 × 30 mL of distilled water in case of PSE
and PPA, respectively by sonication for 30 min. The solu-
tion was filtered into 100 mL volumetric flask and com-
pleted to the volume with the same solvent. Aliquots
covering the working concentration ranges were analyzed
as described under” Construction of the Calibration
Curves”. The concentrations of the drugs were determined
using, either the calibration curves or the corresponding
regression equations.
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• For ephedrine Ampoules
The contents of ten ephedrine ampoules were emp-
tied and mixed well. An accurately measured volume
of the resulting solution equivalent to 10.0 mg of EPH
was transferred into 100 mL volumetric flask, and
diluted to volume with distilled water. Aliquots cover-
ing the working concentration ranges were analyzed as
described under” Construction of the Calibration
curve”. The concentration of EPH was determined
using, either the calibration curves or the correspond-
ing regression equation.
2.4.3. Application of the Proposed Method to the Analysis
of PSE in spiked human urine
Five mL of human urine were spiked with 20, 40, 60 μg/
mL of PSE were transferred into series of centrifugation
tubes, the solutions were then rendered alkaline with
0.5 mL of 5 M KOH to liberate the base, followed by 3 g
of NaCl as described by Avois et al [32]. The spiked
urine is then extracted with three portions each of 2 mL
of ter.-butyl methyl ether (TBME), centrifuged for 5 min-
utes at 2500 g. After centrifugation, the clear supernatant
was collected, evaporated till dryness under nitrogen gas.
The residue was dissolved in 3 mL of distilled water and
completed as described under “Construction of the Cali-
bration Curve.
3. Results and discussion
2,4-dinitrofluorobenzene (DNFB) as an active aryl halide
reacts with primary or secondary amine in aqueous alka-
line medium to form a yellow colored product through a
nucleophilic substitution reaction [33]. The presence of
primary amine in PPA and secondary amine in both of
PSE and EPH which are highly susceptible for derivatiza-
tion reaction with DNFB initiated the present study. In the
present study, the studied drugs were found to react with
DNFB in borate buffer producing a yellow color peaking
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Figure 2 Absorption spectra of the reaction products.
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3.1.1. Study of Experimental Parameters
Experimental parameters affecting color development and
its stability were carefully studied and optimized; each was
changed while others were kept constant. Experimental
parameters include; effect of pH, volume of buffer solu-
tion, volume of DNFB solution, heating time, surface
active agent (SAA), temperature and effect of diluting
solvent.
3.1.1.i. Effect of pH
The reaction between the investigated drugs and DNFB
was investigated over the pH range of 7.0- 9.0 using 0.2
M borate buffer. The reaction showed the highest absor-
bance value in borate buffer of pH 8.0 ± 0.5 for EPH,
PPA and PSE. Therefore, pH 8.0 was selected as the opti-
mum pH value throughout this study (Figure 3).
3.1.1. ii. Effect of volume of buffer solution
It was found that increasing the volume of 0.2 M borate
buffer produced a corresponding increase in the absor-
bance value of the reaction product up to 0.5 mL for PSE
and EPH and 0.8 mL for PPA, and it remained constant
up to 1.0 mL for PSE, 1.2 mL for PPA and 1.5 mL in case
of EPH, respectively (Figure 4). Therefore, 0.8 ± 0.2 mL
for PSE, 1.0 ± 0.2 mL for PPA and 1.0 ± 0.5 mL for EPH
were chosen as the optimum buffer volume for the
analysis.
3.1.1.iii. Effect of the volume of DNFB solution
The influence of the volume of DNFB was studied using
different volumes of 0.3%, (v/v) solution of the reagent. It
was found that increasing volumes of the reagent produced
a proportional increase in the absorbance value up to
0.6 mL for PSE, 0.5 mL for PPA and 0.6 mL for EPH.
However, no further increase in the absorbance value was
achieved upon increasing the volume of the reagent up to
1.2 mL for PSE, 0.7 mL for PPA and 1.0 mL for EPH.
Therefore, 0.8 ± 0.2 mL for PSE, 0.6 ± 0.1 mL for PPA and
0.8 ± 0.2 mL for EPH of 0.3%, (v/v) DNFB solution were
chosen as the optimal volume of the reagent (Figure 5).
Upon the reaction of any of the studied drugs with DNFB
a yellow colored product was attained along with the alka-
line hydrolysis product of DNFB (2,4-dinitrophenolate),
which exhibits an intense yellow color [30]. The spectra of
the two products are overlapped rendering impossible mea-
surement of the analyte derivative. However, upon acidifi-
cation with conc. HCl after the completion of the reaction,
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Figure 3 Effect of the pH of 0.2 M borate buffer on the reaction product.
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the yellow 2, 4-dinitrophenolate turns to the colorless 2, 4-
dinitrophenol, allowing the quantitative measurement of
the Drug-DNFB derivative which remains stable up to
60 min [30].
3.1.1. iv Effect of heating time
The effect of the heating time of the reaction between the
investigated drugs and DNFB was studied. Increasing the
heating time resulted in gradual increase in the absorbance
value of the reaction product up to 20 min for PSE,
15 min for PPA and 20 min for EPH, respectively, after
which no further increase in the absorption intensities
occur. Therefore 25 ± 5 min for PSE, EPH and 20 ± 5 min
for PPA were chosen as the optimum buffer volume
through this approach (Figure 6).
3.1.1. v. Effect of heating temperature
In order to obtain the highest and most stable absor-
bance, the effect of the reaction time and heating tem-
perature was investigated (Figure 7). It was found that,
the reaction proceeds very slowly at room temperature.
A gradual increase in the heating temperature produced
a significant increase in the absorbance of the reaction
product up to 70°C for PSE, 80°C for PPA and EPH,
respectively. Therefore, heating was achieved at 70°C for
PSE, 80°C for PPA and EPH, respectively.
3.1.1. vi Effect of diluting solvent
The effect of diluting solvent was tested using different
solvents viz water, methanol, acetone, acetonitrile,
dimethylformamide, dimethylsulfoxide and isopropanol.
Using water as diluting solvent gave the highest absor-
bance value in case of PSE and PPA while in case of EPH;
the maximum absorbance intensity was produced by using
methanol as a diluting solvent. On the other hand, dilution
with dimethylformamide and dimethylsulfoxide resulted in
high back ground absorbance of the blank.
3.1.1. vii Effect of surface active agent:-
Each of 1%, (w/v) SDS, 1%, (w/v) cetrimide and 1%, (w/v)
tween were tested, hopefully they may increase the absor-
bance value of the reaction product. Unfortunately, no




















      















Figure 4 Effect of the volume of 0.2 M borate buffer on the reaction product.
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marked increase in the absorbance value was observed.
Therefore, the reaction was carried out omitting SAA.
3.1.1. viii Effect of time on the stability of the formed
adduct
The reaction product was found to be stable for at least
60 min at room temperature.
3.2. Validation of the proposed Method
The validity of the proposed methods was tested regard-
ing linearity, specificity, accuracy, repeatability and pre-
cision according to ICH Q2 (R1) recommendations [34].
3.2.1. Linearity
The absorbance concentration plots were rectilinear
over the ranges of 2-20 for PPA and 1-14 μg/mL for
both of EPH and PSE, respectively, cited in Table 1. The
proposed method was evaluated for the accuracy as per-
cent relative error (% Er) and the precision as percent
relative standard deviation (% RSD) (Table 1).
Analysis of the data gave the following regression
equations:
For PPA A = 0.0439 + 0.0496C (r = 0.9998)
For EPH A = 0.0049 + 0.0588C (r = 0.9999)
For PSE A = 0.0109 + 0.0633C (r = 0.9999)
Where A is the Absorbance value
C is the concentration in μg/mL
r is the correlation coefficient
3.2.2. Limit of quantitation and limit of detection
The limits of quantitation (LOQ) and (LOD) were cal-
culated according to ICH Q2 (R1) recommendation
[34]. The results are shown in (Table 1).




Where Sa is the standard deviation of the intercept of
regression line, and b is the slope of the regression line.
3.2.3. Accuracy
To test the validity of the proposed method, it was applied
to the determination of pure sample of PPA, EPH and PSE
over the concentration ranges cited in (Table 2). The
results obtained were in good agreement with those
obtained using the comparison methods [35-37]. Statistical
analysis of the results using Student t-test and the variance
ratio F-test [38] revealed no significance differences
between the performance of the proposed and comparison
methods regarding the accuracy and precision, respectively
(Table 2). The spectrophotometric comparison method
[35] for PPA depends on its determination via reaction















  PSE (10g/mL) with DNFB  
Ÿ PPA (12g/mL) with DNFB  
źEPH (7g/mL) with DNFB 
Figure 5 Effect of volume of reagent on the reaction product.
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Figure 6 Effect of heating time on the reaction product.



















  PSE (10g/mL) with DNFB 
Ÿ PPA (12g/mL) with DNFB. 
źEPH (7 g/mL) with DNFB. 
Figure 7 Effect of heating temperature on the reaction product.
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Table 1 Analytical performance data for the determination of the studied drugs by the proposed spectrophotometric
method
Parameter PPA EPH PSE
Linearity range (μg/mL) 2-20 1-14 1-14
Limit of detection, LOD, (μg/mL) 0.20 0.13 0.20
Limit of quantification, LOQ, (μg/mL) 0.60 0.40 0.59
Correlation coefficient (r) 0.9998 0.9999 0.9999
Slope 0.050 0.059 0.063
Intercept 0.044 0.005 0.011
S.D. of residuals, Sy/x 5.04 ×10
-3 3.00 × 10-3 5.63 ×10-3
S.D. of intercept, Sa 2.99 × 10
-3 2.36 × 10-3 3.76 ×10-3
S.D. of slope, Sb 3.00 × 10
-4 2.75 × 10-4 4.71 × 10-4
Percentage relative standered deviation, % RSD 1.08 0.96 0.99
Percentage error, % Error 0.41 0.34 0.40
Molar absorptivity, ε L.moL1.cm-1 9.3 × 103 1.43 ×104 1.55 × 104
Table 2 Application of the proposed and comparison methods to the determination of the studied drugs in pure
forms






% Founda % Founda
PPA 2.0 1.96 98.00
4.0 4.01 100.25 99.53
6.0 5.97 99.50 102.01




x¯ ± S.D. 99.83 ± 1.08 100.55± 1.29
t 0.339 (2.306)
F 1.426 (5.14)







% Founda % Founda
EPH 1.0 1.02 102.00
3.0 2.98 99.33
5.0 5.02 100.40 102.00
7.0 6.94 99.14 99.98




x¯ ± S.D. 100.18 ± 0.96 100.01 ± 1.01
t 1.264 (2.262)
F 1.106 (4.74)








% Founda % Founda
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with NBD-Cl and measuring the absorbance of the reac-
tion product at 455 nm. The comparison method for EPH
[36] was through Charge transfer reaction using p-chlora-
nil and acetaldehyde and measuring the absorbance of the
reaction product at 680 nm. On the other hand, the com-
parison method for PSE was based on measuring first deri-
vative ratio derivative of PSE in 0.1 N HCl [37].
The validity of the methods was proved by statistical
evaluation of the regression line, using the standard
deviation of the residuals (Sy/x), the standard deviation
of the intercept (Sa) and standard deviation of the slope
(Sb). The results are abridged in (Table 1). The small
values of the figures indicate low scattering of the
calibration points around the calibration line and high
precision.
3.2.4. Precision
3.2.4.i. Repeatability: the repeatability was performed
through replicate analysis of three concentrations of the
three drugs over the specified working concentration
range in pure form on three successive occasions. The
results are presented in (Table 3).
3.2.4.ii. Intermediate precision: intermediate precision
was tested by replicate analysis of the three drugs in
pure form using the concentrations shown in (Table 3)
for a period of 3 successive days. The results are sum-
marized in (Table 3).
Table 2 Application of the proposed and comparison methods to the determination of the studied drugs in pure
forms (Continued)
PSE 1.0 1.01 101.00 102.00
3.0 3.00 100.00 98.33




x¯ ± S.D. 100.02 ± 0.99 99.45 ± 2.22
t 0.597 (2.365)
F 5.028 (5.79)
a Each result is the average of three separate determinations.
*Values between parentheses are the tabulated t and F values, at p 0.05(38).
Table 3 Accuracy and precision data for the determination of the studied drugs by the proposed spectrophotometric
method













PPA 4.0 4.03 100.75 4.0 3.97 99.25
6.0 5.98 99.67 6.0 5.88 98.00
10.0 10.00 100.00 10.0 9.80 98.00
x¯ ± SD 100.14 ± 0.55 98.42 ± 0.72
%RSD 0.55 0.73
%Er 0.32 0.42
EPH 7.0 6.98 99.71 7.0 7.07 101.00
8.0 8.12 101.50 8.0 8.09 101.12
10.0 10.02 100.20 9.0 9.15 101.67
x¯ ± SD 100.47 ± 0.92 101.26 ± 0.36
%RSD 0.91 0.35
%Er 0.52 0.20
PSE 6.0 6.12 102.00* 6. 0 5.96 99.33
10.0 10.23 102.30 10.0 10.07 100.70
12.0 12.29 102.42 12.0 12.09 100.75
x¯ ± SD 102.24 ± 0.22 100.26 ± 0.80
%RSD 0.21 0.80
%Er 0.12 0.46
* Each result is the average of three separate determinations.
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3.2.5. Robustness of the method
The robustness of the proposed method was examined by
evaluating the influence of small, deliberate variations in
the method variables on the absorbance of the reaction
product. The tested variables included; the pH 8.0 ± 0.5 for
the three studied drugs, the change in the volume of the
buffer solution 0.8 ± 0.2 mL for PSE, 1.0 ± 0.2 mL and
1.0 ± 0.5 mL for PPA. The change in the volume of DNFB
0.3%, (v/v), 0.8 ± 0.2 mL for PSE, 0.6 ± 0.1 mL for PPA
and 0.8 ± 0.2 for EPH, the change in the heating time, 25 ±
5 min for PSE and EPH and 20 ± 5 min for PPA. These
minor changes that may take place during the experimen-
tal operation didn’t affect the absorbance of the reaction
product.
3.2.6. Selectivity
The selectivity of the method was investigated by obser-
ving any interference encountered from the common
tablet excipients such as talc, starch, magnesium stearate
and avicil. These excipients didn’t interfere with pro-
posed method (Table 4).
3.2.7. Specificity
The proposed method is specific for the determination
of EPH in the presence of its metabolite (deaminated
form), since the latter is devoid from secondary alipha-
tic amine which is essential for the reaction with
DNFB.
3.3. Pharmaceutical Applications
The proposed method was successfully applied for
determination of the studied drugs in their pharmaceuti-
cal preparations. The results obtained were statistically
compared to those of the comparison methods [35-37].
Using student’s t-test for accuracy and the variance ratio
F-test for precision as recorded in (Table 4) revealed no
significance difference in the performance of the two
methods, respectively.
Table 4 Application of the proposed and comparison methods to the determination of the studied drugs in dosage
form




% Founda % Found
Contaflu tabletsc




















x¯ ± S.D. 101.21f ± 0.94 100.90 ± 1.30
t 0.334 (2.776)*
F 1.913 (19.00)*
a Each result is the average of three separate determinations.
*Values between parentheses are the tabulated t and F values, at p 0.05(38).
a Contaflu tablets, batch # 061342, each tablet labeled to contain 24 mg of phenylpropanolamine HCl, 3 mg of chlorpheniramine maleate and 200 mg of
propyphenazone, product of Egyptian Int..Pharmaceutical Industries CO. E.P.I.CO,10th of Ramadan City, Egypt.
b Ephedrine ampoule:-batch # 11 each ampoule (1 mL) labeled to contain 30 mg of ephedrine HCl, A product of Chemical industries Development(CID)-Giza-A.R.
E.
c Allercet capsule, batch # 820304, each capsule labeled to contain 30 mg pseudoephedrine HCl and 10 mg cetirizine HCl, product of Global Napi
Pharmaceuticals, 6th of October City-Giza-Egypt.
d PPA content found in Contaflu tablet was found to be 23.94 mg/tablet.
e EPH content found in Ephedrine ampoule was found to be 30.34 mg/ampoule.
f PSE content found in Allercet® capsule was found to be 30.36 mg/capsule.
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3.4.Biological analysis
Upon oral administration of 30 mg of PSE, it was found
that up to about 90% of the dose is excreted unchanged
in the urine in 24 hours with less than 1% as norpseu-
doephedrine (cathine) [39]. This initiated the present
study. Such concentration lies within the working con-
centration range of the present study.
Therefore, the proposed method was applied for the
determination of PSE in spiked human urine. The
extraction adopted by Avois et al [32] was applied here
(Table 5).
3.5. Molar ratio and mechanism of the reaction
The stoichiometry of the reaction was studied adopting
the limiting logarithmic method [40]. Plots of log absor-
bance versus log [DNFB] and log [Drug] gave two
straight lines, the slopes of which were 0.57/0.78 for
DNFB/PPA, 0.41/0.37 for DNFB/EPH and 0.72/0.94 for
DNFB/PSE (Figure 8). Hence, it was concluded that the
reaction proceeds in the ratio of 1:1, confirming that
one molecule of the drug condenses with one molecule
of DNFB. Based on the observed molar ratio and by
analogy to previous reports [28], the mechanism of the
reaction is postulated to proceed as shown in the fol-
lowing scheme 1.
4. Conclusion
The proposed spectrophotometric method provided
simple, reproducible and accurate method for determi-
nation of PSE, PPA and EPH. The established method
was validated and applied to determination of the stu-
died drugs in their dosage forms without interference
from common excipients. The developed method
showed to be a simple and suitable technique to quan-
tify these drugs and might be employed for quality con-
trol analysis.
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Figure 8 Limiting logarithmic plots for the molar reactivity.
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